Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg
Details : Mesalamine is a small molecule drug, prostaglandin and leukotriene inhibitor, indicated for the treatment of ulcerative proctitis.
Product Name : Mesalamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edetate Calcium Disodium
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Product Name : Edetate Calcium Disodium-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2023
Lead Product(s) : Edetate Calcium Disodium
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : University of Minnesota
Deal Size : Undisclosed
Deal Type : Collaboration
Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota
Details : Rising Pharmaceuticals and its partner Laurus will supply hydroxychloroquine to support University of Minnesota's study on hydroxychloroquine as a treatment of COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : University of Minnesota
Deal Size : Undisclosed
Deal Type : Collaboration